1. Home
  2. BLX vs BEAM Comparison

BLX vs BEAM Comparison

Compare BLX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLX
  • BEAM
  • Stock Information
  • Founded
  • BLX 1977
  • BEAM 2017
  • Country
  • BLX Panama
  • BEAM United States
  • Employees
  • BLX N/A
  • BEAM N/A
  • Industry
  • BLX Commercial Banks
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BLX Finance
  • BEAM Health Care
  • Exchange
  • BLX Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • BLX 1.5B
  • BEAM 1.6B
  • IPO Year
  • BLX N/A
  • BEAM 2020
  • Fundamental
  • Price
  • BLX $41.23
  • BEAM $17.17
  • Analyst Decision
  • BLX
  • BEAM Strong Buy
  • Analyst Count
  • BLX 0
  • BEAM 11
  • Target Price
  • BLX N/A
  • BEAM $48.90
  • AVG Volume (30 Days)
  • BLX 102.7K
  • BEAM 1.8M
  • Earning Date
  • BLX 07-22-2025
  • BEAM 08-05-2025
  • Dividend Yield
  • BLX 6.07%
  • BEAM N/A
  • EPS Growth
  • BLX 13.55
  • BEAM N/A
  • EPS
  • BLX 5.60
  • BEAM N/A
  • Revenue
  • BLX $289,499,000.00
  • BEAM $63,578,000.00
  • Revenue This Year
  • BLX $13.23
  • BEAM N/A
  • Revenue Next Year
  • BLX $7.79
  • BEAM $8.82
  • P/E Ratio
  • BLX $7.36
  • BEAM N/A
  • Revenue Growth
  • BLX 13.37
  • BEAM N/A
  • 52 Week Low
  • BLX $27.37
  • BEAM $13.53
  • 52 Week High
  • BLX $42.88
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • BLX 51.36
  • BEAM 48.68
  • Support Level
  • BLX $40.66
  • BEAM $16.11
  • Resistance Level
  • BLX $42.29
  • BEAM $17.38
  • Average True Range (ATR)
  • BLX 0.75
  • BEAM 1.02
  • MACD
  • BLX -0.16
  • BEAM 0.03
  • Stochastic Oscillator
  • BLX 26.73
  • BEAM 30.84

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: